Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN
Recruiting · NCT05260671 · Registry updated 2023-10-18Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN | Disease Attributes, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 2 | 2023-10-18 | NCT05260671 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Eye & ENT Hospital of Fudan University | 64 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Department of Radiotherapy, Eye & ENT Hospital of Fudan University | Shanghai | China | 1 |
| Department of radiotherapy,The First Bethune Hospital of Jilin University | Changchun | China | 1 |